Literature DB >> 23136161

Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity.

Philipp Jakob1, Carola Doerries, Sylvie Briand, Pavani Mocharla, Nicolle Kränkel, Christian Besler, Maja Mueller, Costantina Manes, Christian Templin, Christof Baltes, Markus Rudin, Heiner Adams, Mathias Wolfrum, Georg Noll, Frank Ruschitzka, Thomas F Lüscher, Ulf Landmesser.   

Abstract

BACKGROUND: MicroRNAs are key regulators of angiogenic processes. Administration of angiogenic early outgrowth cells (EOCs) or CD34(+) cells has been suggested to improve cardiac function after ischemic injury, in particular by promoting neovascularization. The present study therefore examines regulation of angiomiRs, microRNAs involved in angiogenesis, in angiogenic EOCs and circulating CD34(+) cells from patients with chronic heart failure (CHF) and the role for their cardiac repair capacity. METHODS AND
RESULTS: Angiogenic EOCs and CD34(+) cells were isolated from patients with CHF caused by ischemic cardiomyopathy (n=45) and healthy subjects (n=35). In flow cytometry analyses, angiogenic EOCs were largely myeloid and positive for alternatively activated M2 macrophage markers. In vivo cardiac neovascularization and functional repair capacity were examined after transplantation into nude mice with myocardial infarction. Cardiac transplantation of angiogenic EOCs from healthy subjects markedly increased neovascularization and improved cardiac function, whereas no such effect was observed after transplantation of angiogenic EOCs from patients with CHF. Real-time polymerase chain reaction analysis of 14 candidate angiomiRs, expressed in angiogenic EOCs, revealed a pronounced loss of angiomiR-126 and -130a in angiogenic EOCs from patients with CHF that was also observed in circulating CD34(+) cells. Anti-miR-126 transfection markedly impaired the capacity of angiogenic EOCs from healthy subjects to improve cardiac function. miR-126 mimic transfection increased the capacity of angiogenic EOCs from patients with CHF to improve cardiac neovascularization and function.
CONCLUSIONS: The present study reveals a loss of angiomiR-126 and -130a in angiogenic EOCs and circulating CD34(+) cells from patients with CHF. Reduced miR-126 expression was identified as a novel mechanism limiting their capacity to improve cardiac neovascularization and function that can be targeted by miR-126 mimic transfection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23136161     DOI: 10.1161/CIRCULATIONAHA.112.093906

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  45 in total

Review 1.  Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.

Authors:  Nazila Nouraee; Seyed Javad Mowla; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2015-03-31       Impact factor: 5.006

Review 2.  Exosome and its roles in cardiovascular diseases.

Authors:  Wang Zhao; Xi-Long Zheng; Shui-Ping Zhao
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

3.  Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis.

Authors:  Patrizia Danieli; Giuseppe Malpasso; Maria Chiara Ciuffreda; Elisabetta Cervio; Laura Calvillo; Francesco Copes; Federica Pisano; Manuela Mura; Lennaert Kleijn; Rudolf A de Boer; Gianluca Viarengo; Vittorio Rosti; Arsenio Spinillo; Marianna Roccio; Massimiliano Gnecchi
Journal:  Stem Cells Transl Med       Date:  2015-03-30       Impact factor: 6.940

Review 4.  Developing miRNA therapeutics for cardiac repair in ischemic heart disease.

Authors:  Kai Zhu; Dingqian Liu; Hao Lai; Jun Li; Chunsheng Wang
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 5.  Therapeutic angiogenesis with exosomal microRNAs: an effectual approach for the treatment of myocardial ischemia.

Authors:  Toktam Moghiman; Bita Barghchi; Seyed-Alireza Esmaeili; Mahmoud Mohammadzadeh Shabestari; Seyedeh Samaneh Tabaee; Amir Abbas Momtazi-Borojeni
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

6.  Hypoxia-responsive microRNA-101 promotes angiogenesis via heme oxygenase-1/vascular endothelial growth factor axis by targeting cullin 3.

Authors:  Ji-Hee Kim; Kwang-Soon Lee; Dong-Keon Lee; Joohwan Kim; Su-Nam Kwak; Kwon-Soo Ha; Jongseon Choe; Moo-Ho Won; Byung-Ryul Cho; Dooil Jeoung; Hansoo Lee; Young-Guen Kwon; Young-Myeong Kim
Journal:  Antioxid Redox Signal       Date:  2014-07-29       Impact factor: 8.401

Review 7.  New strategies for improving stem cell therapy in ischemic heart disease.

Authors:  Peisen Huang; Xiaqiu Tian; Qing Li; Yuejin Yang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 8.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

9.  Downregulation of connexin43 by microRNA-130a in cardiomyocytes results in cardiac arrhythmias.

Authors:  Appledene Osbourne; Tyler Calway; Michael Broman; Saoirse McSharry; Judy Earley; Gene H Kim
Journal:  J Mol Cell Cardiol       Date:  2014-05-10       Impact factor: 5.000

Review 10.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.